Chimeric antigen receptor (CAR)-T cell therapy has transformed haematological cancer treatment but remains limited by intrinsic T cell constraints. This Review discusses emerging CAR-engineered immune cells beyond conventional T cells, highlighting how their distinct biological features, tailored manufacturing strategies, and specialized CAR designs address key challenges and expand the therapeutic potential of CAR-based immunotherapy.
